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Abstract
In a prospective study in 124 Japanese women with estrogen receptor-positive (ERD) invasive early breast
cancer (EBC), the effect of the 21-gene assay on adjuvant decision-making was examined. Overall, treatment
recommendations changed in 33% (95% conﬁdence interval [CI], 24%-43%) of node-negative (N0) and 65%
(95% CI, 41%-85%) of node-positive (ND) patients, predominantly from chemohormonal to hormonal therapy.
Results from this Japanese population conﬁrm US and European experiences.
Background: In this study we investigated if the 21-gene assay result affects adjuvant decision-making in Japanese
women with ERþ invasive EBC. Patients and Methods: A total of 124 consecutive eligible patients with ERþ, HER2-
negative EBC and 0 to 3 positive lymph nodes were enrolled. Treatment recommendations, physicians’ conﬁdence and
patients’decisional conﬂict before and after knowledge of the RecurrenceScore results of the 21-gene assaywere recorded.
Results: One-hundred fourpatients (84%)hadN0disease, includingmicrometastases, and20 (16%)hadNþdisease.Overall,
recommendations changed in 33% (95%CI, 24%-43%)ofN0and65% (95%CI, 41%-85%)ofNþ patients. In 27of 48 (56%)
of N0 and 13 of 15 (87%) of Nþ patients an initial recommendation for chemohormonal therapy was revised to only hormonal
therapy after assay results, and in 7of 56 (13%)ofN0and0of 5Nþ patients fromonly hormonal to combinedchemohormonal
therapy. Decisions appeared to follow the Recurrence Score results for low and high values. For patients with intermediate
Recurrence Score values, overall recommendations for chemohormonal treatment tended to decrease after assay results.
Physicians’ conﬁdence increased in 106 of 124 (85.5%; 95% CI, 78%-91%) cases. Patients’ decisional conﬂict signiﬁcantly
improved as indicatedby changes in the total score and the 5deﬁned subscores (P¼ .014 for InformedSubscore;P< .001 for
all others).Conclusion: Results from this prospective study in a Japanese population conﬁrm an effect of the 21-gene assay
results on adjuvant treatment decision-making, consistent with reported experiences from the United States and Europe.cal Breast Cancer, Vol. 14, No. 3, 191-7 ª 2014 The Authors. Published by Elsevier Inc.
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The incidence of breast cancer is still increasing in Japan.1
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192 -75% of Japanese breast cancer cases.3 Routinely, such patients
receive adjuvant hormonal treatment. Many of these patients are
also treated with adjuvant chemotherapy although a substantial
proportion will not derive any clinical beneﬁt in terms of a further
reduction of their risk of recurrence.4 Recently, the traditional
instrumentarium of clinical and histopathological prognostic
markers has been complemented by genomic markers such as the
multigene 21-gene Recurrence Score assay.
The 21-gene assay measures the mRNA expression of 16 cancer-
related and 5 reference genes selected based on correlation of
gene expression and risk of distant recurrence in 3 development
studies.5-7 The assay is based on reverse transcription polymerase
chain reaction, which was speciﬁcally optimized to be used in
archival formalin-ﬁxed, parafﬁn-embedded tumor tissue,8,9 and can
thus be performed on routinely processed and archived tumor
blocks or slides. Using an algorithm based on the results of clinical
studies, the Recurrence Score result—a numeric score between
0 and 100—is calculated.10 The score is a continuous variable
quantifying the risk of distant recurrence at 10 years for the indi-
vidual patient10 with estrogen receptor-positive (ERþ) early breast
cancer treated with adjuvant hormonal therapy. A lower Recurrence
Score value corresponds to a lower risk of recurrence, and a higher
value corresponds to a higher risk of recurrence. Three risk cate-
gories have been deﬁned: low, intermediate, and high risk groups for
Recurrence Score values < 18, 18 to 30, and  31, respectively.10
The prognostic signiﬁcance of the 21-gene assay for node-negative
(N0) and node-positive (Nþ) disease has been validated using
tumor specimens from patients with ERþ early breast cancer
enrolled prospectively in large randomized phase III studies.4,10-12
Furthermore, the assay was shown to be predictive of the beneﬁt
of chemotherapy in N0 and Nþ ERþ patients.4,12 Patients with
tumors that had a high Recurrence Score result had the largest
proportional beneﬁt of chemotherapy, and those presenting with
a tumor with a score < 18, did not appear to beneﬁt from
chemotherapy.
The 21-gene assay has been included in guidelines of scientiﬁc
societies such as American Society of Clinical Oncology,13 National
Comprehensive Cancer Network (NCCN),14 and European Society
for Medical Oncology.15 The updated 2011 St Gallen Consensus
Panel acknowledges the test as the only multiparameter gene assay
considered useful, not only as a prognostic test, but also as a marker
predictive of chemotherapy responsiveness in hormone receptor-
positive early breast cancer where uncertainty remains after
consideration of other tests.16
Several clinical utility studies have demonstrated that knowledge
of Recurrence Score results affects management of patients. Results
of these retrospective and prospective studies are very consistent
for N0 ERþ disease and show a revision of treatment recommen-
dations in approximately 35% of cases as reported in a recent
metaanalysis.17 Recommendations shift predominantly from adju-
vant chemohormonal treatment to hormonal treatment alone. The
database for Nþ disease is still evolving.18,19 Results suggest a
similar effect for patients with 1 to 3 positive lymph nodes.
It was also shown that the 21-gene assay was applicable to adjuvant
therapy decision-making beyond the largely Caucasian populations in
which it was originally validated. A recently published conﬁrmatory
study demonstrated that the assay provided prognostic information inClinical Breast Cancer June 2014a population of Japanese women with ERþ N0 early breast cancer
treated with adjuvant tamoxifen.2 Notably, the authors reported that
the expression proﬁles of individual genes and gene groups for the
Japanese patients were very similar to those for the patients from the
validation study National Surgical Adjuvant Breast and Bowel Project
B-14: A Clinical trial to assess Tamorifen in patients with primary
breast cancer and negative axillary nodes whose tumors are positive for
estrogen receptors with conﬁdence intervals for the hazard ratios for
distant recurrence for the 2 studies overlapping for all genes and gene
groups. Physicians in Japan have started to use the assay as a tool in
routine adjuvant decision-making. Japanese guidelines describe the
assay as an option for consideration to aid decisions on whether
chemotherapy should be used for hormone receptor-positive breast
cancer in the adjuvant setting.20 However, thus far, no prospective
clinical utility data of the 21-gene assay have been generated in a
population of women in Japan. Thus, we conducted a clinical study to
analyze the inﬂuence of Recurrence Score information on the adjuvant
decision-making process in Japanese patients with ERþ N0 or Nþ
early-stage breast cancer.
Patients and Methods
This was a prospective, multicenter study performed in 2 Japa-
nese centers. The study was approved by the respective institutional
ethics committees. All patients provided written informed consent.
Study Objectives
The primary study objective was to characterize the degree to
which Recurrence Score results affect physician recommendations
for adjuvant therapy and physicians’ expressed level of conﬁdence in
the recommended treatment plan in a cohort of consecutive patients
with ERþ, HER2-negative breast cancer with up to 3 positive
lymph nodes.
A secondary study objective was to assess the effect of assay results
on patients’ level of decisional conﬂict. An additional secondary
objective was to provide a basis for indirect estimates of net cost
effects and savings from a Japanese societal perspective that might
result from using the assay. This health economic assessment is
beyond the scope of the current report.
Patients
Enrollment was offered consecutively to eligible women who
had operable ERþ, HER2-negative breast cancer, either with N0
(pre-and postmenopausal patients) or micrometastatic disease
(postmenopausal patients) or with histologically veriﬁed lymph
node metastases in 1 to 3 lymph nodes (postmenopausal patients
only). Patients had to be 18 years of age or older with adequate
performance status to be candidates for systemic chemotherapy,
and to be able to give consent and answer written questions in
Japanese. To participate in the study, patients were required to incur
the costs of the assay as an out-of-pocket expense.
Physicians
Seventeen physicians participated in the study. They had to be
either medical oncologists or surgeons making adjuvant treatment
recommendations to breast cancer patients. At least 1 physician of a
participating center needed to have previously ordered the 21-gene
assay.
Hideko Yamauchi et alPhysician Questionnaires
A baseline questionnaire developed for use in this study on the
basis of a published questionnaire21 captured physicians’ initial
treatment recommendations, largely based on effective Japanese20
and NCCN guidelines,14 and answers to queries regarding their
conﬁdence in their treatment recommendations before the assay was
performed. A follow-up questionnaire recorded physicians’ treat-
ment recommendations and conﬁdence in their recommendations
after knowledge of the assay results. For the latter, physicians
responded to the statement “I am more conﬁdent in my treatment
recommendation after ordering the assay” according to a Likert scale
with the options: “strongly disagree,” “disagree,” “neither disagree
nor agree,” “agree,” “strongly agree,” and “do not know.”
Patient Questionnaires and Decisional Conﬂict Scale
At baseline and after results of the assay were discussed, patients
completed the 16-item Decisional Conﬂict Scale (DCS). This scale
has been validated to assess patient perceptions of uncertainty in
making decisions about health care treatment options and satisfac-
tion with treatment decision-making.22,23 Regarding the DCS, the
test-retest (2 weeks later) reliability coefﬁcient was 0.81. Internal
consistency coefﬁcients ranged from 0.78 to 0.92.
The DCS has a Total Score and 5 subscores: the Informed,
Values Clarity, Support, and Uncertainty Subscores are based on 3
items each and the Effective Decision Subscore is based on the
remaining 4 items.
Statistical Methods
The proportion of patients whose treatment recommendations
changed from baseline to follow-up was calculated along with the
respective 95% conﬁdence interval (CI) using the Clopper-Pearson
method. McNemar’s test was used to assess whether the proportion
of patients who were initially recommended chemotherapy wasTable 1 Patient Characteristics
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Data are reported as n (%) excepte where otherwise noted.
Abbreviations: N0 ¼ node-negative; Nþ ¼ node-positive.changed after the 21-gene assay. These analyses were conducted
separately according to nodal status (N0, including micrometastases
[N1mic], vs. Nþ), and combined. The proportion of cases in which
the physician either agreed or strongly agreed that they were more
conﬁdent in their treatment recommendation after the assay was
calculated along with the respective 95% CI.
The DCS data from the baseline and follow-up questionnaires
were analyzed similarly. Each of the 5 subscores was calculated
as the sum of the component items only if there were responses to
each of the deﬁned items, and transformed to a range from 0 to 100
with smaller scores reﬂecting less decisional conﬂict. If any subscore
was missing, the Total Score was set to missing. If all 5 subscores
were not missing, then the Total Score was calculated as:
Total Score ¼ (3  [Informed Subscore] þ 3  [Values Clarity
Subscore] þ 3  [Support Subscore] þ 3  [Uncertainty
Subscore] þ 4  [Effective Decision Subscore])/16. The changes
from baseline to follow-up in the DCS Total Score and each of the
subscores were analyzed using paired-sample t tests.
The study was designed to enroll 200 patients, with the original
intent to estimate a decision change rate of 20% with a precision
of 5% to 6%. However, it was decided to halt enrollment
after 124 patients were enrolled because the accumulating data
indicated that there were statistically signiﬁcant reductions in
treatment recommendations for chemotherapy in N0 and Nþ
patient subgroups.
Results
Patient and Tumor Characteristics
One-hundred twenty-four patients were enrolled between July
2009 and June 2011. Complete patient and tumor characteristics
and the distribution of Recurrence Score values are listed in Table 1.
In the N0 subset, 50 (48%) patients had a low score< 18, 37 (36%)
had an intermediate score of 18 to 30, and 17 (16%) had a highN0 (n [ 104) ND (1-3 Positive Nodes) (n [ 20)
49.8 59.9
63 (60.6) 13 (65.0)
41 (39.4) 7 (35.0)
31 (29.8) 13 (65.0)
30 (28.8) 5 (25.0)
43 (41.3) 2 (10.0)
62 (59.6) 0 (0.0)
42 (40.4) 20 (100.0)
50 (48.1) 12 (60.0)
37 (35.6) 7 (35.0)
17 (16.3) 1 (5.0)
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Table 2 Chemotherapy Recommendations Before and After





HT 54 (44%) 7 (6%) 61 (49%)
CHT 40 (32%) 23 (19%) 63 (51%)
All 94 (76%) 30 (24%) 124
Node-Negative Patients
Before Assay
HT 49 (47%) 7 (7%) 56 (54%)
CHT 27 (26%) 21 (20%) 48 (46%)
All 76 (73%) 28 (27%) 104
Node-Positive Patients
Before Assay
HT 5 (25%) 0 (0%) 5 (25%)
CHT 13 (65%) 2 (10%) 15 (75%)
All 18 (90%) 2 (10%) 20
McNemar’s test exact P < .001.
Abbreviations: CHT ¼ chemohormonal therapy; HT ¼ hormonal therapy.
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194 -score of  31. Distribution of patients in the smaller Nþ subset
according to risk group was 12 (60%) patients with low, 7 (35%)
with intermediate, and 1 (5%) with high Recurrence Score values.
Treatment Recommendations Before and After Knowledge
of Recurrence Score Result
Treatment recommendations before and after the 21-gene assay
are listed in Table 2. Initial treatment recommendations were
revised in 47 of 124 (38%; 95% CI, 29%-47%) of all patients,
34 of 104 (33%; 95% CI, 24%-43%) of patients with N0 and 13
of 20 (65%; 95% CI, 41%-85%) of patients with Nþ disease after
knowledge of the Recurrence Score results.Figure 1 Recommendation for Adjuvant Chemotherapy Pre- and Po
Abbreviation: RS ¼ Recurrence Score result.
Regardless of nodal status.
Clinical Breast Cancer June 2014For all patients recommended chemohormonal therapy
(CHT) before the assay, treatment recommendations were revised
to hormomal therapy (HT) only in 40 of 63 (63%; 95% CI, 50%-
75%) total patients, including 27 of 48 (56%; 95% CI, 41%-
71%) with N0 disease, and 13 of 15 (87%; 95% CI, 60%-98%)
with Nþ disease. For all patients initially recommended HT
alone, the recommendations after assay changed to CHT in 7 of
61 (11%; 95% CI, 5%-22%) total patients, all 7 of whom were
from those 56 patients with N0 disease (13%; 95% CI, 5%-24%).
Overall, the shift in treatment recommendations was predomi-
nantly from CHT to HT (P < .001 for N0 patients and P < .001
for Nþ patients by McNemar’s test), ultimately resulting in a
net reduction of adjuvant chemotherapy (Table 2 and Fig. 1).
All patients in the low Recurrence Score group were recommended
HT and, similarly, 100% of patients in the high Recurrence
Score group were recommended CHT, indicating that for N0 and
Nþ patients, treatment recommendations after assay appeared to
directly follow the low and high Recurrence Score categorizations
(Fig. 1). For patients with intermediate Recurrence Score values, in
N0 patients recommendations for CHT decreased by an absolute
19%, and in Nþ patients by an absolute of 86% after the assay
(Table 3).
Physicians’ Conﬁdence in Treatment Recommendation
Physicians either agreed or strongly agreed that they were
more conﬁdent in their treatment recommendations after the assay
in 106 of 124 (85%; 95% CI, 78%-91%) cases. Physicians dis-
agreed in 7% of cases and neither agreed nor disagreed in 8% of
cases (Fig. 2).
Patients’ Decisional Conﬂict Before and After the 21-Gene
Assay
The Total Score of the Decisional Conﬂict Scale before and
after assay was available for 116 patients. The mean values of the
5 subscores and the Total Score are listed in Table 4. Each of the
5 subscores and the Total Score decreased signiﬁcantly (P ¼ .014st-Assay
Table 3 Changes in Treatment Recommendations
Patients n
Overall Change Rate,
Before to After Assay CHT to HT HT to CHT No Change CHT to CHT HT to HT
All Evaluable 124 47 (38%; 95% CI, 29%-47%) 40 (32%) 7 (6%) 77 (62%) 23 (19%) 54 (44%)
Low RS 62 23 (37%) 23 (37%) 0 (0%) 39 (63%) 0 (0%) 39 (63%)
Intermediate RS 44 21 (48%) 17 (39%) 4 (9%) 23 (52%) 8 (18%) 15 (34%)
High RS 18 3 (17%) 0 (0%) 3 (17%) 15 (83%) 15 (83%) 0 (0%)
Node-Negative 104 34 (33%; 95% CI, 24%-43%) 27 (26%) 7 (7%) 70 (67%) 21 (20%) 49 (47%)
Low RS 50 16 (32%) 16 (32%) 0 (0%) 34 (68%) 0 (0%) 34 (68%)
Intermediate RS 37 15 (41%) 11 (30%) 4 (11%) 22 (59%) 7 (19%) 15 (41%)
High RS 17 3 (18%) 0 (0%) 3 (18%) 14 (82%) 14 (82%) 0 (0%)
Node-Positive 20 13 (65%; 95% CI, 41%-85%) 13 (65%) 0 (0%) 7 (35%) 2 (10%) 5 (25%)
Low RS 12 7 (58%) 7 (58%) 0 (0%) 5 (42%) 0 (0%) 5 (42%)
Intermediate RS 7 6 (86%) 6 (86%) 0 (0%) 1 (14%) 1 (14%) 0 (0%)
High RS 1 0 (0%) 0 (0%) 0 (0%) 1 (100%) 1 (100%) 0 (0%)
95% Conﬁdence intervals calculated using the Clopper-Pearson method.
Abbreviations: CHT ¼ chemohormonal therapy; HT ¼ hormonal therapy; RS ¼ Recurrence Score result.
Hideko Yamauchi et alfor Informed Subscore; P < .001 for all others), indicating an
overall reduction in patients’ decisional conﬂict after knowledge of
the Recurrence Score result. The mean Total Score improved by
26% after patients received the assay results.
Discussion
This is the ﬁrst study of the effect of the 21-gene assay on clinical
decision-making in early invasive breast cancer in an Asian patient
population. Moreover, our study is one of the ﬁrst decision impact
studies for the assay that includes N0 and Nþ patients.
Regarding N0 disease, the results of our study are consistent
with those reported from other prospective decision impact studies
from the United States,21 Spain,24 and Germany.19 Overall change
rates in these prospective studies ranged from 30% to 32%. The
metaanalysis of 9 studies and 1154 patients reported a change rate
of 35%.17 We found an overall change rate of 33%. Change ratesFigure 2 Change in Physicians’ Conﬁdence After The 21-Gene Assa
Abbreviation: RS ¼ Recurrence Score result.
Answers to the question (post-RS): “I am more conﬁdent in my treatment recommendation.”in the United Kingdom25 and Australia18 were somewhat lower
with 27% and 24%, perhaps in part because the proportion of
patients with an initial recommendation for chemotherapy in
these studies was much lower (40% and 24%, respectively), than
in our study (51%) and the other 3 cited. However, regardless of
baseline tendencies to use either more conservative or aggressive
treatment approaches across all studies to date, decision changes
attributable to the 21-gene assay appear to occur in both
directions—foregoing chemotherapy in many patients, and adding
it in others.
Regarding Nþ disease, results vary among other studies of the
effect of Recurrence Score results in Nþ early breast cancer pati-
ents. A retrospective study in 135 patients with ERþ disease
including 9 patients with N1mic and 11 patients with Nþ disease
found an overall change rate in treatment recommendations of
25%. The authors found no correlation of therapy change andy
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Table 4 Changes From Before Assay to After Assay in Decisional Conﬂict
Score na Pre-RS Mean Post-RS Mean Mean Change (95% CI) P b
Informed Subscore 121 26.2 22.1 4.1 (0.9-7.4) .014
Values Clarity Subscore 122 28.6 22.3 6.2 (2.9-9.5) <.001
Support Subscore 120 22.6 17.6 5.0 (2.2-7.8) <.001
Uncertainty Subscore 121 44.6 30.5 14.0 (9.0-19.1) <.001
Effective Decision Subscore 122 24.3 17.7 6.6 (3.9-9.2) <.001
Total Score 116 28.8 21.4 7.4 (4.7-10.0) <.001
Abbreviation: RS ¼ Recurrence Score result.
aNumber of patients for whom all items were not missing for the pre-assay and the post-assay questionnaires.
bP value from paired t test.
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196 -nodal stage.26 A US Web-based retrospective physician survey
reported a change rate of 51% in 138 Nþ ERþ patients with a
change from CHT to HT in 33%.27 In the Australian study,18 the
Recurrence Score result led to a 26% change in treatment recom-
mendations in 50 patients with 1 to 3 positive lymph nodes: 12
patients changed to HT and 1 to CHT. In the German study there
was a 39% change rate in 122 patients, with a predominant change
from CHT to HT in 28% of all Nþ cases and a 37% change
among the 92 Nþ patients with an initial recommendation for
CHT.19 In this study, we saw a 65% (95% CI, 41%-85%) shift in
treatment recommendations in the 20 Nþ patients, with all changes
made from CHT to HT. These patients all had low and interme-
diate Recurrence Score values. It should be noted that we only
offered the test to Nþ patients who were postmenopausal, in
accordance with the validation study in Nþ disease.12 This was not
a prerequisite in the other studies cited. Thus, physicians in our
study might more readily have omitted chemotherapy. Further-
more, because all patients were required to pay out-of-pocket for the
cost of the assay, the study might have preselected patients who were
more inclined and generally more conﬁdent to forego chemotherapy
from the outset. The small number of patients with Nþ disease in
our study is a major limitation to drawing more general conclusions,
and further studies might be warranted to better deﬁne the effect of
the assay when offered to Nþ patients.
Generally, for patients in the low and in the high Recurrence
Score groups, treatment recommendations after assay corresponded
completely with the Recurrence Score results in our study. The US,
Spanish, and German studies have similarly observed that the shifts
in treatment recommendations followed the Recurrence Score
values. However, although all patients with high Recurrence Score
results were recommended chemotherapy in these studies, a small
minority of patients in the low Recurrence Score groups remained
with recommendations for chemotherapy despite Recurrence Score
values < 18. For physicians in our study, the assay appeared to be
the ﬁnal decisive parameter after consideration of all other factors.
One explanation might be that patients might have been more
motivated to avoid chemotherapy, particularly if their scores were
low, because they paid out-of-pocket for the assay in this study.
For patients in this study with intermediate Recurrence Score
results, the physicians appeared to have taken the continuous nature
of the score into account, because the tendency to change from
CHT to HT was greater for patients with low-intermediate scores
between 18 and 25 compared with those with high-intermediate
scores from 26 to 30. It should also be noted that the assay wasClinical Breast Cancer June 2014not offered to patients in whom a clear decision for the type of
adjuvant therapy had already been made.
Similar to other studies, we found that physicians’ conﬁdence
in their treatment recommendation increased in 85% of cases.
In comparison, changes in physician conﬁdence levels were 76% in
the US study,21 60% in the Spanish study,24 46% in the Australian
study,28 and 45% in the German study.19 Although all decision
impact studies report sizable increases in physician conﬁdence
after receipt of Recurrence Score information, the wide range of
improvements in physician conﬁdence might reﬂect differences in
baseline experience with use of the 21-gene assay among physician
investigators in each study.
In our assessment of patients’ decisional conﬂict, we found each of
the 5 subscores and the Total Score to improve signiﬁcantly, indi-
cating overall reduction in patients’ decisional conﬂict with knowl-
edge of the Recurrence Score results. The mean total Decisional
Conﬂict Score improved by 26% after knowledge of the Recurrence
Score results. The analysis of the Decisional Conﬂict Scale in the US
study21 was conducted on the raw Total Scores. Applying the scaling
rules used in our study to enable comparison, the mean Total Score
decreased from 24.8 to 17.3, a reduction of 7.5 units, which is
comparable with the mean reduction of 7.4 units seen in our study.Conclusion
The results from this Japanese population conﬁrm an effect of the
21-gene assay on adjuvant treatment decision-making, consistent
with studies in predominantly Caucasian populations in North
America and Europe. Moreover, results indicate that the Recurrence
Score values were adopted as a critical tool in adjuvant decision-
making in ERþ early breast cancer in centers with previous expe-
rience with the assay. The use of the assay ultimately resulted in a
net reduction in treatment recommendations for adjuvant chemo-
therapy. The effect on the Japanese health care system should be
assessed systematically. In another article we report on health eco-
nomic analyses assessing the cost-effectiveness of an adjuvant
decision-making process guided by the 21-gene assay for the Japa-
nese health care system.Clinical Practice Points
 The 21-gene assay was shown to be of prognostic signiﬁcance
and to be predictive of the beneﬁt of chemotherapy in patients
with estrogen receptor positive early breast cancer in both node-
negative and node-positive disease.
Hideko Yamauchi et al A conﬁrmatory study in a population of Japanese women with
ERþ node-negative early breast cancer treated with adjuvant
tamoxifen demonstrated that it also provided prognostic infor-
mation beyond the largely Caucasian populations it was origi-
nally validated in.
 The 21-gene assay has been included in guidelines of major
scientiﬁc societies.
 Several clinical utility studies have demonstrated that knowledge
of Recurrence Score results affects management of patients.
 In node-negative ER-positive disease results consistently show a
revision of treatment recommendations in approximately 35% of
cases and a predominant shift of recommendations from adju-
vant chemohormonal treatment to hormonal treatment alone.
 Similar effects have been described for patients with 1 to 3
positive lymph nodes.
 The results of this prospective study in a Japanese population
conﬁrm an impact of the 21-gene assay on adjuvant treatment
decision-making, consistent with studies in predominantly
Caucasian populations in North America and Europe.
 The use of the assay ultimately resulted in a net reduction in
treatment recommendations for adjuvant chemotherapy as well
as an increase in physicians’ conﬁdence and an improvement in
patients’ decisional conﬂict.
 The data may contribute to a wider adoption of the 21-gene
assay as a critical tool in adjuvant decision-making in ERþ early
breast cancer in Japanese clinical practice.
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